Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation

Haematologica. 2022 Dec 1;107(12):2990. doi: 10.3324/haematol.2022.281988.
No abstract available

Publication types

  • Published Erratum

MeSH terms

  • B-Lymphocyte Subsets*
  • Humans
  • Interleukin-1 Receptor-Associated Kinases*
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / genetics
  • Mutation
  • Myeloid Differentiation Factor 88 / genetics
  • NF-kappa B* / antagonists & inhibitors
  • NF-kappa B* / metabolism
  • Receptors, Interleukin-1

Substances

  • Interleukin-1 Receptor-Associated Kinases
  • Myeloid Differentiation Factor 88
  • NF-kappa B
  • Receptors, Interleukin-1
  • IRAK1 protein, human